ImmunoCellular Therapeutics (IMUC) 10-Q2017 Q2 Quarterly report

Filed: 14 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abuse, addressing, altogether, Anderson, animal, arrangement, Baltimore, bankruptcy, body, Caltech, complement, component, conserve, convenience, County, David, dercognition, derecgonition, derecognition, DNA, durable, duty, enrichment, explore, extent, fact, fiduciary, floor, function, goal, hematopoietic, holder, indemnify, indirectly, inserting, kill, killer, Laureate, lesser, Los, lowest, Mandatorily, Maryland, MD, mismanagement, motivated, National, Nobel, penalty, post, potent, receptor, relinquish, renew, round, salvage, scheme, sequence, sequencing, served, shut, simply, solid, spent, Stanford, TCR, tranche, transformed, travel, UMB, unjust, waste, Wiener, wrote

Removed: Absent, accrue, admitting, agree, anniversary, begun, Blood, bulk, cancel, cancelable, capitalized, classification, consent, denying, desist, economical, entry, environment, execution, Food, formal, hired, IND, LPS, mutually, ordering, outset, packaging, Peripheral, postpone, processing, randomizing, reflected, refundable, room, schedule, secured, settlement, Somatic, storage, winding, writing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

IMUC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:


1.	The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and


2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: August 14, 2017	By:	/s/ Anthony Gringeri
		Name:	Anthony Gringeri, Ph.D.
		Title:	President and Chief Executive Officer